Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-11-2017 | Letter to the Editor

Dosimetry in clinical radionuclide therapy: the devil is in the detail

Authors: Francesco Giammarile, Kristoff Muylle, Roberto Delgado Bolton, Jolanta Kunikowska, Uwe Haberkorn, Wim Oyen

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 12/2017

Excerpt

Radionuclide therapy (RNT), also known as “targeted”, “metabolic” or “molecular” radiotherapy, uses open (i.e. “unsealed”) radioactive isotopes, and is generally administered orally or intravenously, enabling delivery of a high radiation dose to the target, while minimizing toxicity to normal tissues. This systemic form of radiation therapy has distinct similarities to, but also profound differences from, the more commonly used external beam radiotherapy (EBRT). From another perspective, RNT can be better characterized as a tumour-selective treatment modality with more similarities to systemic chemotherapy [1]. …

Brans B, Bodei L, Giammarile F, Linden O, Luster M, Oyen WJ, et al. Clinical radionuclide therapy dosimetry: the quest for the "holy gray". Eur J Nucl Med Mol Imaging. 2007;34(5):772–86.CrossRefPubMedPubMedCentral

Chiesa C, Sjogreen Gleisner K, Flux G, Gear J, Walrand S, Chouin N, et al. The conflict between treatment optimization and registration of radiopharmaceuticals with fixed activity posology in oncological nuclear medicine therapy. Eur J Nucl Med Mol Imaging. 2017. https://doi.org/10.1007/s00259-017-3707-3.PubMedCentral

DeNardo GL, Juweid ME, White CA, Wiseman GA, DeNardo SJ. Role of radiation dosimetry in radioimmunotherapy planning and treatment dosing. Crit Rev Oncol Hematol. 2001;39:203–18.CrossRefPubMed

Sandström M, Garske-Román U, Granberg D, Johansson S, Widström C, Eriksson B, et al. Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment. J Nucl Med. 2013;54(1):33–41.CrossRefPubMed

Pouget J-P, Mather SJ. General aspects of the cellular response to low- and high-LET radiation. Eur J Nucl Med. 2001;28:541–61.CrossRefPubMed

Boyd M, Ross SC, Dorrens J, Fullerton NE, Tan KW, Zalutsky MR, et al. Radiation-induced biological bystander effect elicited in vitro by targeted radiopharmaceuticals labelled with α-, β-, and auger electron-emitting radionuclides. J Nucl Med. 2006;47:1007–15.PubMed

Granzotto A, Devic C, Viau M, Maalouf M, Joubert A, Massart C, et al. Individual susceptibility to radiosensitivity and to genomic instability: its impact on low- dose phenomena. Health Phys. 2011;100(3):282.CrossRefPubMed

Barnett GC, Coles CE, Elliott RM, Baynes C, Luccarini C, Conroy D, et al. Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study. Lancet Oncol. 2012;13(1):65–77.CrossRefPubMed

Title: Dosimetry in clinical radionuclide therapy: the devil is in the detail
Authors: Francesco Giammarile
Kristoff Muylle
Roberto Delgado Bolton
Jolanta Kunikowska
Uwe Haberkorn
Wim Oyen
Publication date: 01-11-2017
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 12/2017
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-017-3820-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Dosimetry in clinical radionuclide therapy: the devil is in the detail

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 12/2017

About the specificity of radiotracers for prostate cancer

Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial

Volumetric parameters on FDG PET can predict early intrahepatic recurrence-free survival in patients with hepatocellular carcinoma after curative surgical resection

Poor predictive value of positive interim FDG-PET/CT in primary mediastinal large B-cell lymphoma

[18F]FDG PET/CT features for the molecular characterization of primary breast tumors

Erratum to: Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F–DOPA